Who
Martyn D. Greenacre
Director
Company insider
Files Form 4 as: Director, Curis; Director, Lisata Therapeutics; Director, Cephalon; Director, BMP Sunstone; Director, Acusphere; Director, Orchestra Therapeutics.
In numbers
- Trades disclosed
- 156
- Buys
- 3
- Sells
- 12
- Bought
- $45K
- Sold
- $5.3M
- Companies
- 6
- Companies where not an officer
- 6
- First trade
- 9 Jan 2006
- Last trade
- 7 Jul 2026
- Last filed
- 9 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 7 Jul 2026filed 9 Jul 2026 | CRIS Curisoption or derivative · Biotechnology | SEC FORM 4 Code A | $36K6,800 at $5.29 | filing |
| 7 Jul 2026filed 9 Jul 2026 | CRIS Curisoption or derivative · Biotechnology | SEC FORM 4 Code A | $36K6,800 at $5.29 | filing |
| 20 May 2025filed 22 May 2025 | CRIS Curisoption or derivative · Biotechnology | SEC FORM 4 Code A | $45K14,400 at $3.13 | filing |
| 28 Jan 2025filed 30 Jan 2025 | CRIS Curisoption or derivative · Biotechnology | SEC FORM 4 Code A | $5,0081,600 at $3.13 | filing |
| 21 May 2024filed 23 May 2024 | CRIS Curisoption or derivative · Biotechnology | SEC FORM 4 Code A | $49K4,250 at $11.62 | filing |
| 23 Jan 2023filed 24 Jan 2023 | CRIS Curisoption or derivative · Biotechnology | SEC FORM 4 Code A | —85,000 at $0.00 | filing |
| 31 Jan 2022filed 31 Jan 2022 | CRIS Curisoption or derivative · Biotechnology | SEC FORM 4 Code A | —85,000 at $0.00 | filing |
| 28 Jan 2021filed 29 Jan 2021 | CRIS Curisoption or derivative · Biotechnology | SEC FORM 4 Code A | —33,000 at $0.00 | filing |
| 2 Mar 2020filed 4 Mar 2020 | CRIS Curisoption or derivative · Biotechnology | SEC FORM 4 Code A | —180,000 at $0.00 | filing |
| 23 Jan 2019filed 25 Jan 2019 | CRIS CurisBiotechnology | SEC FORM 4 Sold | $19K18,500 at $1.05 | filing |
| 21 Jan 2019filed 23 Jan 2019 | CRIS Curisoption or derivative · Biotechnology | SEC FORM 4 Code A | —180,000 at $0.00 | filing |
| 22 Jan 2018filed 24 Jan 2018 | CRIS CurisBiotechnology | SEC FORM 4 Code A | —185,000 at $0.00 | filing |
| 31 May 2017filed 2 Jun 2017 | CRIS CurisBiotechnology | SEC FORM 4 Code M | $14K10,000 at $1.39 | filing |
| 31 May 2017filed 2 Jun 2017 | CRIS CurisBiotechnology | SEC FORM 4 Code M | $6,9505,000 at $1.39 | filing |
| 31 May 2017filed 2 Jun 2017 | CRIS CurisBiotechnology | SEC FORM 4 Code F | $21K12,193 at $1.71 | filing |
| 31 May 2017filed 2 Jun 2017 | CRIS Curisoption or derivative · Biotechnology | SEC FORM 4 Code M | —10,000 at $0.00 | filing |
| 31 May 2017filed 2 Jun 2017 | CRIS Curisoption or derivative · Biotechnology | SEC FORM 4 Code M | —5,000 at $0.00 | filing |
| 28 Feb 2017filed 2 Mar 2017 | CRIS Curisoption or derivative · Biotechnology | SEC FORM 4 Code A | —120,000 at $0.00 | filing |
| 27 May 2016filed 27 May 2016 | CRIS CurisBiotechnology | SEC FORM 4 Code M | $8,3505,000 at $1.67 | filing |
| 27 May 2016filed 27 May 2016 | CRIS CurisBiotechnology | SEC FORM 4 Sold | $8,4505,000 at $1.69 | filing |
News
Reviewing Soligenix (NASDAQ:SNGX) and Curis (NASDAQ:CRIS)CRIS · themarketsdaily.com · 17 Oct 2026Lisata Therapeutics Appoints Jeff Farrow to Board of DirectorsLSTA · manilatimes.net · 14 Oct 2026Analyzing Lisata Therapeutics (NASDAQ:LSTA) & Praxis Precision Medicines (NASDAQ:PRAX)LSTA · tickerreport.com · 11 Oct 2026Lisata Therapeutics wins new US patent for pancreatic cancer drugLSTA · proactiveinvestors.com · 8 Oct 2026
0 headlines in the last 90 days name Martyn D. Greenacre; 4 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.